TKIs

• 

Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations

By Sharon Deveson Kell|2022-11-21T09:01:40+00:0021 Nov 2022|Drug treatments|

This study looked at real world information from patients with [...]

Read More

Comments Off on Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations

• 

Side effect management for kidney cancer treatments

By Sharon Deveson Kell|2022-11-16T12:16:24+00:008 Nov 2022|Drug treatments|

At the International Kidney Cancer Symposium (IKCS) in the USA [...]

Read More

Comments Off on Side effect management for kidney cancer treatments

• 

Treatment of rare subtypes of kidney cancer

By Robert|2022-11-09T09:50:57+00:007 Nov 2022|Uncategorized|

At the  International Kidney Cancer Symposium (IKCS) in North America [...]

Read More

Comments Off on Treatment of rare subtypes of kidney cancer

• 

ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease

By Sharon Deveson Kell|2022-09-14T08:26:50+00:009 Sep 2022|Drug treatments|

The results of COSMIC-131 were presented at the European Society [...]

Read More

Comments Off on ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease

• 

Reduced starting dose of TKI is comparable to a full dose in metastatic kidney cancer

By Sharon Deveson Kell|2022-08-23T06:59:38+00:0023 Aug 2022|Drug treatments|

A study published in the Journal of Hematology Oncology Pharmacy [...]

Read More

Comments Off on Reduced starting dose of TKI is comparable to a full dose in metastatic kidney cancer

• 

ASCO 2022: Sequencing of kidney cancer medicines

By Sharon Deveson Kell|2022-06-21T14:19:37+00:0021 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology (ASCO)  Annual Meeting [...]

Read More

Comments Off on ASCO 2022: Sequencing of kidney cancer medicines

• 

Sequencing of treatments for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-06-14T08:25:47+00:0014 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology Annual Meeting earlier [...]

Read More

Comments Off on Sequencing of treatments for advanced/metastatic kidney cancer

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

EIKCS 2022: Debate about later-line treatments

By Sharon Deveson Kell|2022-04-25T13:44:50+00:0025 Apr 2022|Drug treatments|

At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]

Read More

Comments Off on EIKCS 2022: Debate about later-line treatments

• 

EIKCS 2022: Which is the best combination therapy?

By Sharon Deveson Kell|2022-04-25T13:45:22+00:0025 Apr 2022|Drug treatments|

During 2022 European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]

Read More

Comments Off on EIKCS 2022: Which is the best combination therapy?